Neogen Corporation Finance Lease, Right-of-Use Asset, Amortization
Neogen Corporation (NEOG) reported Finance Lease, Right-of-Use Asset, Amortization of $100.00 thousand for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-07-30
- Neogen Corporation finance lease, right-of-use asset, amortization for fiscal 2026 was $100.00K, a 66.67% decline from fiscal 2025.
- Neogen Corporation finance lease, right-of-use asset, amortization for fiscal 2025 was $300.00K, a 36.99% increase from fiscal 2024.
- Neogen Corporation finance lease, right-of-use asset, amortization for fiscal 2024 was $219.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|
| 2026-05-31 | $100.00K 10-K · filed 2026-07-30 | |
| 2025-05-31 | $300.00K 10-K · filed 2026-07-30 | $299.00K 10-K · filed 2025-07-30 |
| 2024-05-31 | $219.00K 10-K · filed 2025-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |